| pubmed-article:21216932 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21216932 | lifeskim:mentions | umls-concept:C0011923 | lld:lifeskim |
| pubmed-article:21216932 | lifeskim:mentions | umls-concept:C1524059 | lld:lifeskim |
| pubmed-article:21216932 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:21216932 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:21216932 | lifeskim:mentions | umls-concept:C1709060 | lld:lifeskim |
| pubmed-article:21216932 | lifeskim:mentions | umls-concept:C0449445 | lld:lifeskim |
| pubmed-article:21216932 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21216932 | pubmed:dateCreated | 2011-2-10 | lld:pubmed |
| pubmed-article:21216932 | pubmed:abstractText | High-content screening is increasingly used to elucidate changes in cellular biology arising from treatment with small molecules and biological probes. We describe a cell classifier for automated analysis of multiparametric data from immunofluorescence microscopy and characterize the phenotypes of 41 cell-cycle modulators, including several protein kinase inhibitors in preclinical and clinical development. This method produces a consistent assessment of treatment-induced phenotypes across experiments done by different biologists and highlights the prevalence of nonuniform and concentration-dependent cellular response to treatment. Contrasting cell phenotypes from high-content screening to kinase selectivity profiles from cell-free assays highlights the limited utility of enzyme potency ratios in understanding the mechanism of action for cell-cycle kinase inhibitors. Our cell-level approach for assessing phenotypic outcomes is reliable, reproducible and capable of supporting medium throughput analyses of a wide range of cellular perturbations. | lld:pubmed |
| pubmed-article:21216932 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21216932 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21216932 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21216932 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21216932 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21216932 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21216932 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21216932 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:21216932 | pubmed:issn | 1538-8514 | lld:pubmed |
| pubmed-article:21216932 | pubmed:author | pubmed-author:LowJonathanJ | lld:pubmed |
| pubmed-article:21216932 | pubmed:author | pubmed-author:SutherlandJef... | lld:pubmed |
| pubmed-article:21216932 | pubmed:author | pubmed-author:EnglerThomas... | lld:pubmed |
| pubmed-article:21216932 | pubmed:author | pubmed-author:StancatoLouis... | lld:pubmed |
| pubmed-article:21216932 | pubmed:author | pubmed-author:DowlessMichel... | lld:pubmed |
| pubmed-article:21216932 | pubmed:author | pubmed-author:BlosserWayneW | lld:pubmed |
| pubmed-article:21216932 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21216932 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:21216932 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21216932 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21216932 | pubmed:pagination | 242-54 | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:meshHeading | pubmed-meshheading:21216932... | lld:pubmed |
| pubmed-article:21216932 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21216932 | pubmed:articleTitle | A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. | lld:pubmed |
| pubmed-article:21216932 | pubmed:affiliation | Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. sutherlandje@lilly.com | lld:pubmed |
| pubmed-article:21216932 | pubmed:publicationType | Journal Article | lld:pubmed |
